Trial · NCT01712659
Participant flow45
How many started, completed or left each group, period by period.
1 to 20 of 45
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Dose Escalation | STARTED | Original Phase II Standard Ruxolitinib Dose Cohort - 20 mg Twice Daily | 1 | |
| Dose Escalation | STARTED | 2- Phase 1 Dose Escalation Cohorts Dose Level 1 - 30 mg Twice Daily | 5 | |
| Dose Escalation | STARTED | 2- Phase 1 Dose Escalation Cohorts Dose Level 2 - 40 mg Twice Daily | 1 | |
| Dose Escalation | STARTED | 2- Phase 1 Dose Escalation Cohorts Dose Level 3 - 50 mg Twice Daily | 0 | |
| Dose Escalation | STARTED | 3- Phase 1 Dose Expansion Cohort | 0 | |
| Dose Escalation | COMPLETED | Original Phase II Standard Ruxolitinib Dose Cohort - 20 mg Twice Daily | 1 | |
| Dose Escalation | COMPLETED | 2- Phase 1 Dose Escalation Cohorts Dose Level 1 - 30 mg Twice Daily | 3 | |
| Dose Escalation | COMPLETED | 2- Phase 1 Dose Escalation Cohorts Dose Level 2 - 40 mg Twice Daily | 1 | |
| Dose Escalation | COMPLETED | 2- Phase 1 Dose Escalation Cohorts Dose Level 3 - 50 mg Twice Daily | 0 | |
| Dose Escalation | COMPLETED | 3- Phase 1 Dose Expansion Cohort | 0 | |
| Dose Escalation | NOT COMPLETED | Original Phase II Standard Ruxolitinib Dose Cohort - 20 mg Twice Daily | 0 | |
| Dose Escalation | NOT COMPLETED | 2- Phase 1 Dose Escalation Cohorts Dose Level 1 - 30 mg Twice Daily | 2 | |
| Dose Escalation | NOT COMPLETED | 2- Phase 1 Dose Escalation Cohorts Dose Level 2 - 40 mg Twice Daily | 0 | |
| Dose Escalation | NOT COMPLETED | 2- Phase 1 Dose Escalation Cohorts Dose Level 3 - 50 mg Twice Daily | 0 | |
| Dose Escalation | NOT COMPLETED | 3- Phase 1 Dose Expansion Cohort | 0 | |
| Dose Expansion | STARTED | Original Phase II Standard Ruxolitinib Dose Cohort - 20 mg Twice Daily | 12 | |
| Dose Expansion | STARTED | 2- Phase 1 Dose Escalation Cohorts Dose Level 1 - 30 mg Twice Daily | 0 | |
| Dose Expansion | STARTED | 2- Phase 1 Dose Escalation Cohorts Dose Level 2 - 40 mg Twice Daily | 0 | |
| Dose Expansion | STARTED | 2- Phase 1 Dose Escalation Cohorts Dose Level 3 - 50 mg Twice Daily | 0 | |
| Dose Expansion | STARTED | 3- Phase 1 Dose Expansion Cohort | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01712659/flow